[
    [
        {
            "time": "2021-12-05",
            "original_text": "贝达药业第四代EGFR抑制剂BPI-361175在美国获批临床",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-361175",
                    "EGFR抑制剂",
                    "美国",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业第四代EGFR抑制剂BPI-361175在美国获批临床",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-05",
            "original_text": "贝达药业：BPI-361175片获美国FDA新药临床试验批准通知书",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-361175",
                    "FDA",
                    "新药",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：BPI-361175片获美国FDA新药临床试验批准通知书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-12-05",
            "original_text": "医药行业周报：医保谈判尘埃落定，看好本土创新发力",
            "features": {
                "keywords": [
                    "医药行业",
                    "医保谈判",
                    "本土创新"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：医保谈判尘埃落定，看好本土创新发力",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-05",
            "original_text": "医保国谈结果公布，国产四款PD-1仅恒瑞新增适应症未出现",
            "features": {
                "keywords": [
                    "医保国谈",
                    "PD-1",
                    "恒瑞",
                    "适应症"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医保国谈结果公布，国产四款PD-1仅恒瑞新增适应症未出现",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]